\-\ Texto\\:\\ \ \(0\)\
\-\ right\\ sided\\ proptosis\\,\\ otherwise\\ wnl\ \(0\)\
\-\ this\\ patient\\ has\\ been\\ treated\\ with\\ chemotherapy\\ since\\ august\\ 2004\\ due\\ to\\ the\\ proptosis\\ caused\\ by\\ the\\ mass\\.\\ chemotherapy\\ agents\\ include\\ carboplatin\\ and\\ vincristine\\.\\ thus\\ far\\ the\\ mass\\ has\\ had\\ a\\ minimal\\ decrease\\ in\\ size\\.\ \(0\)\
\-\ right\\ sided\\ intraconal\\ solid\\ spherical\\ mass\\ continuous\\ with\\ the\\ optic\\ nerve\\.\\ meninges\\ appear\\ to\\ be\\ intact\\ around\\ mass\\ with\\ csf\\ surrounding\\ mass\\.\\ mass\\ appears\\ to\\ be\\ confined\\ within\\ orbit\\ and\\ does\\ not\\ involve\\ the\\ optic\\ chiasm\\.\\ the\\ signal\\ intensity\\ of\\ the\\ mass\\ in\\ t1w\\ images\\ is\\ similar\\ to\\ the\\ signal\\ intensity\\ of\\ the\\ optic\\ nerves\\ and\\ brain\\ matter\\.\\ on\\ t2w\\ images\\,\\ the\\ mass\\ again\\ has\\ similar\\ intensity\\ to\\ the\\ optic\\ nerves\\ and\\ brain\\ matter\\ and\\ has\\ a\\ higher\\ intensity\\ than\\ the\\ musculature\\.\\ on\\ t1w\\ images\\,\\ post\\-gadolinium\\,\\ the\\ mass\\ shows\\ fairly\\ uniform\\ contrast\\ enhancement\ \(0\)\
\-\ optic\\ nerve\\ glioma\ \(11\)\
\-\ most\\ common\\ orbital\\ malignancies\\ of\\ children\\:\ \(0\)\
\-\ rhabdomyosarcoma\\ \\(primary\\)\ \(0\)\
\-\ neuroblastoma\\ \\(usually\\ metastatic\\)\ \(0\)\
\-\ retinoblastoma\\ \\(intraocular\\)\ \(0\)\
\-\ most\\ common\\ orbital\\ masses\\:\ \(0\)\
\-\ benign\\ cysts\\ \\(teratoma\\,\\ dermoid\\,\\ epidermoid\\,\\ congenital\\ cystic\\ eye\\)\ \(0\)\
\-\ vascular\\ lesions\\ \\(capillary\\ hemangioma\\,\\ cavernous\\ hemangioma\\,\\ avm\\,\\ lymphangioma\\)\ \(0\)\
\-\ neurogenic\\ orbital\\ masses\\ of\\ children\\:\ \(0\)\
\-\ optic\\ nerve\\ glioma\ \(11\)\
\-\ optic\\ sheath\\ meningioma\ \(1\)\
\-\ sphenoid\\ wing\\ meningioma\ \(0\)\
\-\ schwannoma\ \(67\)\
\-\ neurofibroma\ \(78\)\
\-\ less\\ common\\ considerations\\:\ \(0\)\
\-\ langerhans\\â\\€\\™\\ cell\\ histiocytosis\ \(0\)\
\-\ lacrimal\\ gland\\ lesions\\ \\(cysts\\,\\ tumors\\)\ \(0\)\
\-\ inflammatory\\ process\\ or\\ infection\ \(0\)\
\-\ 2\\ y\\.o\\.\\ noted\\ to\\ have\\ right\\ sided\\ proptosis\ \(1\)\
\-\ the\\ pediatric\\ patient\\ presenting\\ with\\ proptosis\\ should\\ always\\ make\\ the\\ clinician\\ think\\ of\\ rhabdomyosarcoma\\.\\ although\\ this\\ tumor\\ accounts\\ for\\ only\\ about\\ 10\\%\\ of\\ all\\ orbital\\ tumors\\,\\ it\\ is\\ the\\ most\\ common\\ primary\\ malignancy\\ of\\ the\\ orbit\\ and\\ is\\ rapidly\\ progressive\\ and\\ destructive\\.\\ for\\ this\\ reason\\,\\ children\\ with\\ proptosis\\,\\ decreased\\ vision\\,\\ or\\ ptosis\\ should\\ promptly\\ be\\ imaged\\ with\\ either\\ ct\\ or\\ mri\\ \\(ct\\ is\\ better\\ to\\ evaluate\\ for\\ bony\\ invasion\\ of\\ rhabdomyosarcoma\\)\\ to\\ evaluate\\ for\\ a\\ mass\\ suspicious\\ for\\ rhabdomyosarcoma\\.\\ other\\ masses\\ in\\ the\\ differential\\ include\\ orbital\\ cysts\\ \\(which\\ are\\ the\\ most\\ common\\ orbital\\ mass\\ and\\ generally\\ benign\\)\\,\\ vascular\\ lesions\\,\\ neurogenic\\ tumors\\ as\\ listed\\ above\\,\\ and\\ metastatic\\ disease\\ \\(of\\ which\\,\\ neuroblastoma\\ is\\ the\\ most\\ common\\ malignancy\\ to\\ metastasize\\ to\\ the\\ orbit\\)\\.\\ cysts\\ of\\ the\\ orbit\\ are\\ by\\ far\\ the\\ most\\ common\\,\\ with\\ dermoid\\ and\\ epidermoid\\ cysts\\ accounting\\ for\\ about\\ 30\\-46\\%\\ of\\ all\\ orbital\\ masses\\;\\ vascular\\ lesions\\ account\\ for\\ about\\ 15\\%\\;\\ neurogenic\\ tumors\\ and\\ metastatic\\ tumors\\ both\\ account\\ for\\ about\\ 2\\-3\\%\\ each\\.\ \(0\)\
\-\ this\\ patient\\ had\\ an\\ mri\\ series\\ of\\ the\\ orbits\\ done\\,\\ revealing\\ a\\ retrobulbar\\ mass\\ and\\ the\\ findings\\ listed\\ above\\.\\ with\\ the\\ mass\\ continuous\\ with\\ the\\ optic\\ nerve\\ and\\ encapsulated\\ by\\ the\\ optic\\ nerve\\ sheath\\,\\ it\\ makes\\ the\\ diagnosis\\ of\\ an\\ optic\\ nerve\\ tumor\\ much\\ more\\ likely\\ than\\ the\\ other\\ possible\\ diagnoses\\ in\\ the\\ differential\\.\\ as\\ the\\ mass\\ has\\ meninges\\ smoothly\\ lining\\ it\\ and\\ there\\ is\\ csf\\ visualized\\ between\\ the\\ mass\\ and\\ the\\ dura\\,\\ the\\ mass\\ is\\ most\\ likely\\ a\\ part\\ of\\ the\\ optic\\ nerve\\â\\€\\”leading\\ to\\ the\\ diagnosis\\ of\\ optic\\ nerve\\ glioma\\.\ \(0\)\
\-\ an\\ optic\\ nerve\\ glioma\\ is\\ actually\\ a\\ juvenile\\ pilocytic\\ astrocytoma\\ of\\ the\\ optic\\ nerve\\,\\ which\\ is\\ a\\ benign\\ and\\ usually\\ slow\\ growing\\ tumor\\.\\ ong\\ accounts\\ for\\ about\\ 20\\%\\ of\\ neurogenic\\ tumors\\ in\\ the\\ orbit\\,\\ there\\ is\\ possibly\\ a\\ mild\\ predilection\\ for\\ females\\,\\ and\\ it\\ usually\\ presents\\ by\\ 8\\ years\\ of\\ age\\.\\ the\\ presenting\\ signs\\ and\\ symptoms\\ are\\ typically\\ slow\\ progressing\\ painless\\ proptosis\\,\\ visual\\ loss\\,\\ nystagmus\\,\\ strabismus\\,\\ and\\ optic\\ atrophy\\ or\\ edema\\.\\ about\\ 29\\%\\ of\\ cases\\ are\\ associated\\ with\\ neurofibromatosis\\ type\\ i\\â\\€\\”typically\\ presenting\\ with\\ bilateral\\ optic\\ nerve\\ gliomas\\.\\ at\\ the\\ time\\ of\\ diagnosis\\,\\ about\\ 25\\-30\\%\\ of\\ gliomas\\ involve\\ only\\ the\\ intraorbital\\ optic\\ nerve\\,\\ about\\ 60\\-70\\%\\ of\\ gliomas\\ involve\\ the\\ chiasm\\,\\ of\\ which\\ about\\ 40\\%\\ have\\ invaded\\ surrounding\\ structures\\.\\ \ \(0\)\
\-\ management\\ of\\ optic\\ nerve\\ gliomas\\ is\\ typically\\ conservative\\,\\ involving\\ regular\\ interval\\ physical\\ exams\\ and\\ mri\\ imaging\\ to\\ evaluate\\ for\\ changes\\ in\\ size\\ \\(physical\\ exam\\ every\\ 6\\ months\\ and\\ mri\\ every\\ 1\\ year\\)\\.\\ this\\ is\\ because\\ ongs\\ are\\ benign\\,\\ slow\\ growing\\ tumors\\,\\ and\\ in\\ up\\ to\\ 80\\%\\ of\\ cases\\,\\ vision\\ does\\ decline\\ some\\ but\\ then\\ remains\\ stable\\.\\ surgical\\ and\\ radiologic\\ intervention\\ result\\ in\\ loss\\ of\\ vision\\ and\\ are\\ usually\\ only\\ offered\\ if\\ vision\\ loss\\ or\\ proptosis\\ progresses\\,\\ or\\ the\\ tumor\\ begins\\ invading\\ the\\ chiasm\\ or\\ hypothalamus\\.\\ chemotherapy\\ is\\ also\\ available\\ and\\ is\\ becoming\\ a\\ more\\ popular\\ form\\ of\\ treatment\\,\\ as\\ it\\ can\\ avoid\\ the\\ possible\\ complete\\ loss\\ of\\ vision\\ and\\ neurotoxic\\ effects\\ of\\ surgery\\ and\\ radiation\\.\\ chemotherapy\\ drugs\\ being\\ used\\ include\\ carboplatin\\ and\\ vincristine\\,\\ and\\ several\\ studies\\ have\\ recommended\\ that\\ chemotherapy\\ with\\ these\\ drugs\\ be\\ first\\-line\\ treatment\\ for\\ optic\\ nerve\\ gliomas\\ that\\ involve\\ the\\ chiasm\\ and\\/or\\ hypothalamus\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ optic\\:\\ 0\\.090990816431588\ \(0\)\
\-\ nerve\\:\\ 0\\.04845798988418279\ \(0\)\
\-\ proptosis\\:\\ 0\\.04044463691637244\ \(0\)\
\-\ about\\:\\ 0\\.03589166774205601\ \(0\)\
\-\ orbital\\:\\ 0\\.03435037702685374\ \(0\)\
\-\ gliomas\\:\\ 0\\.034125088339095354\ \(0\)\
\-\ tumors\\:\\ 0\\.0272009860819534\ \(0\)\
\-\ orbit\\:\\ 0\\.02605725736954993\ \(0\)\
\-\ neurogenic\\:\\ 0\\.02547297996356942\ \(0\)\
\-\ chiasm\\:\\ 0\\.024590066855608377\ \(0\)\
\-\ \\%\\:\\ 0\\.02413221590007273\ \(0\)\
\-\ vision\\:\\ 0\\.023898208072099972\ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.023284190018082455\ \(0\)\
\-\ mass\\:\\ 0\\.023021036454190114\ \(0\)\
\-\ cysts\\:\\ 0\\.020263064666049435\ \(0\)\
\-\ involve\\:\\ 0\\.019506182475469504\ \(0\)\
\-\ common\\:\\ 0\\.018951417050477943\ \(0\)\
\-\ carboplatin\\:\\ 0\\.01868500274890651\ \(0\)\
\-\ glioma\\:\\ 0\\.018657015950152983\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.018540834050489497\ \(0\)\
\-\ slow\\:\\ 0\\.016800957682591062\ \(0\)\
\-\ most\\:\\ 0\\.016718941879051492\ \(0\)\
\-\ intensity\\:\\ 0\\.014957242984887657\ \(0\)\
\-\ hypothalamus\\:\\ 0\\.01463179104534314\ \(0\)\
\-\ meninges\\:\\ 0\\.014485000193487366\ \(0\)\
\-\ benign\\:\\ 0\\.014281115578853277\ \(0\)\
\-\ masses\\:\\ 0\\.013988340910392675\ \(0\)\
\-\ vincristine\\:\\ 0\\.013973355898893645\ \(0\)\
\-\ listed\\:\\ 0\\.013551192733894183\ \(0\)\
\-\ children\\:\\ 0\\.013407582728437915\ \(0\)\
\-\ \\,\\:\\ 0\\.013109446272023602\ \(0\)\
\-\ accounts\\:\\ 0\\.0130303419357902\ \(0\)\
\-\ presenting\\:\\ 0\\.012649393331844295\ \(0\)\
\-\ usually\\:\\ 0\\.012566238517514572\ \(0\)\
\-\ evaluate\\:\\ 0\\.012545615950086221\ \(0\)\
\-\ continuous\\:\\ 0\\.012127980470208665\ \(0\)\
\-\ loss\\:\\ 0\\.012011933038588085\ \(0\)\
\-\ t1w\\:\\ 0\\.011872870262804727\ \(0\)\
\-\ far\\:\\ 0\\.011686523916228146\ \(0\)\
\-\ account\\:\\ 0\\.011686523916228146\ \(0\)\
\-\ it\\:\\ 0\\.011627411528650222\ \(0\)\
\-\ sided\\:\\ 0\\.011475278255980553\ \(0\)\
\-\ growing\\:\\ 0\\.011431413708824209\ \(0\)\
\-\ drugs\\:\\ 0\\.011431413708824209\ \(0\)\
\-\ sheath\\:\\ 0\\.01139139118593992\ \(0\)\
\-\ lesions\\:\\ 0\\.011077774849123234\ \(0\)\
\-\ every\\:\\ 0\\.010989957154843688\ \(0\)\
\-\ 30\\-46\\:\\ 0\\.010672540464850482\ \(0\)\
\-\ nerve\\â\\€\\”leading\\:\\ 0\\.010672540464850482\ \(0\)\
\-\ ong\\:\\ 0\\.010672540464850482\ \(0\)\
\-\ i\\â\\€\\”typically\\:\\ 0\\.010672540464850482\ \(0\)\
\-\ ongs\\:\\ 0\\.010672540464850482\ \(0\)\
\-\ neurotoxic\\:\\ 0\\.010672540464850482\ \(0\)\
\-\ for\\:\\ 0\\.010592370198199252\ \(0\)\
\-\ nerves\\:\\ 0\\.01050407169367625\ \(0\)\
\-\ neuroblastoma\\:\\ 0\\.010344367171177954\ \(0\)\
\-\ vascular\\:\\ 0\\.010176040924662337\ \(0\)\
\-\ epidermoid\\:\\ 0\\.009856141151581715\ \(0\)\
\-\ has\\:\\ 0\\.009713680208803135\ \(0\)\
\-\ tumor\\:\\ 0\\.009647614051384075\ \(0\)\
\-\ is\\:\\ 0\\.009530352176012299\ \(0\)\
\-\ mri\\:\\ 0\\.009507389127915836\ \(0\)\
\-\ dermoid\\:\\ 0\\.009432294184354414\ \(0\)\
\-\ strabismus\\:\\ 0\\.009342501374453254\ \(0\)\
\-\ only\\:\\ 0\\.00933200360224553\ \(0\)\
\-\ hemangioma\\:\\ 0\\.009245293341894391\ \(0\)\
\-\ \\(\\:\\ 0\\.00874529934919928\ \(0\)\
\-\ popular\\:\\ 0\\.008724068415898787\ \(0\)\
\-\ first\\-line\\:\\ 0\\.008724068415898787\ \(0\)\
\-\ include\\:\\ 0\\.008706368600594263\ \(0\)\
\-\ csf\\:\\ 0\\.00864042215933659\ \(0\)\
\-\ \\)\\:\\ 0\\.00863847084882936\ \(0\)\
\-\ or\\:\\ 0\\.00848748092342125\ \(0\)\
\-\ are\\:\\ 0\\.00846155355348379\ \(0\)\
\-\ 25\\-30\\:\\ 0\\.00831671703984405\ \(0\)\
\-\ 60\\-70\\:\\ 0\\.00831671703984405\ \(0\)\
\-\ invaded\\:\\ 0\\.00831671703984405\ \(0\)\
\-\ retrobulbar\\:\\ 0\\.008155056758216298\ \(0\)\
\-\ intraorbital\\:\\ 0\\.008155056758216298\ \(0\)\
\-\ matter\\:\\ 0\\.008146440606297331\ \(0\)\
\-\ similar\\:\\ 0\\.008115463968379874\ \(0\)\
\-\ malignancy\\:\\ 0\\.007995374522521831\ \(0\)\
\-\ meningioma\\:\\ 0\\.00795663277592028\ \(0\)\
\-\ intraocular\\:\\ 0\\.00788490718035406\ \(0\)\
\-\ the\\:\\ 0\\.007866484722845535\ \(0\)\
\-\ metastatic\\:\\ 0\\.007812746017976114\ \(0\)\
\-\ which\\:\\ 0\\.007724671124661253\ \(0\)\
\-\ intraconal\\:\\ 0\\.0076641789033637985\ \(0\)\
\-\ think\\:\\ 0\\.0076641789033637985\ \(0\)\
\-\ above\\:\\ 0\\.007583386577791324\ \(0\)\
\-\ promptly\\:\\ 0\\.0075672748989164184\ \(0\)\
\-\ encapsulated\\:\\ 0\\.00739402932550156\ \(0\)\
\-\ metastasize\\:\\ 0\\.00731589552267157\ \(0\)\
\-\ typically\\:\\ 0\\.007303694357157318\ \(0\)\
\-\ spherical\\:\\ 0\\.007242500096743683\ \(0\)\
\-\ becoming\\:\\ 0\\.007242500096743683\ \(0\)\
\-\ ptosis\\:\\ 0\\.0071733010485113\ \(0\)\
\-\ diagnosis\\:\\ 0\\.007126704591212179\ \(0\)\
\-\ retinoblastoma\\:\\ 0\\.0071078443641647195\ \(0\)\
\-\ does\\:\\ 0\\.007059615182527861\ \(0\)\
\-\ lacrimal\\:\\ 0\\.0070457459448093306\ \(0\)\
\-\ accounting\\:\\ 0\\.0070457459448093306\ \(0\)\
\-\ offered\\:\\ 0\\.0070457459448093306\ \(0\)\
\-\ possible\\:\\ 0\\.006968479948871845\ \(0\)\
\-\ size\\:\\ 0\\.006936745451280319\ \(0\)\
\-\ smoothly\\:\\ 0\\.006930358317927582\ \(0\)\
\-\ decline\\:\\ 0\\.006930358317927582\ \(0\)\
\-\ progresses\\:\\ 0\\.006930358317927582\ \(0\)\
\-\ cases\\:\\ 0\\.006893004513271507\ \(0\)\
\-\ by\\:\\ 0\\.006890415996343219\ \(0\)\
\-\ invading\\:\\ 0\\.006876542624742553\ \(0\)\
\-\ lining\\:\\ 0\\.006825017667819071\ \(0\)\
\-\ predilection\\:\\ 0\\.006825017667819071\ \(0\)\
\-\ progressing\\:\\ 0\\.006825017667819071\ \(0\)\
\-\ surrounding\\:\\ 0\\.006801852940350522\ \(0\)\
\-\ orbits\\:\\ 0\\.00672811366337169\ \(0\)\
\-\ to\\:\\ 0\\.006721410907698331\ \(0\)\
\-\ have\\:\\ 0\\.006720719412948275\ \(0\)\
\-\ lymphangioma\\:\\ 0\\.006682423193658801\ \(0\)\
\-\ revealing\\:\\ 0\\.006682423193658801\ \(0\)\
\-\ clinician\\:\\ 0\\.0066383945687545935\ \(0\)\
\-\ should\\:\\ 0\\.006596146590529783\ \(0\)\
\-\ malignancies\\:\\ 0\\.006595911130726421\ \(0\)\
\-\ differential\\:\\ 0\\.006568909998433244\ \(0\)\
\-\ dura\\:\\ 0\\.006554868089956831\ \(0\)\
\-\ wing\\:\\ 0\\.0065151709678951\ \(0\)\
\-\ reason\\:\\ 0\\.0065151709678951\ \(0\)\
\-\ nystagmus\\:\\ 0\\.0065151709678951\ \(0\)\
\-\ post\\-gadolinium\\:\\ 0\\.006439480463075082\ \(0\)\
\-\ begins\\:\\ 0\\.006439480463075082\ \(0\)\
\-\ be\\:\\ 0\\.006381388490769633\ \(0\)\
\-\ august\\:\\ 0\\.006368244990892355\ \(0\)\
\-\ musculature\\:\\ 0\\.006368244990892355\ \(0\)\
\-\ imaged\\:\\ 0\\.006368244990892355\ \(0\)\
\-\ actually\\:\\ 0\\.006368244990892355\ \(0\)\
\-\ and\\:\\ 0\\.0063199287726807924\ \(0\)\
\-\ confined\\:\\ 0\\.0062372358085191915\ \(0\)\
\-\ brain\\:\\ 0\\.006226032744074485\ \(0\)\
\-\ destructive\\:\\ 0\\.006206584709264603\ \(0\)\
\-\ primary\\:\\ 0\\.006129259716454471\ \(0\)\
\-\ langerhans\\:\\ 0\\.006119029428901859\ \(0\)\
\-\ diagnoses\\:\\ 0\\.006119029428901859\ \(0\)\
\-\ capillary\\:\\ 0\\.006091197082382854\ \(0\)\
\-\ agents\\:\\ 0\\.006063990235104333\ \(0\)\
\-\ fairly\\:\\ 0\\.006063990235104333\ \(0\)\
\-\ uniform\\:\\ 0\\.006063990235104333\ \(0\)\
\-\ effects\\:\\ 0\\.006037381389197825\ \(0\)\
\-\ avoid\\:\\ 0\\.005985856432274343\ \(0\)\
\-\ considerations\\:\\ 0\\.005960893614837617\ \(0\)\
\-\ images\\:\\ 0\\.005953742948968599\ \(0\)\
\-\ all\\:\\ 0\\.005852114986516443\ \(0\)\
\-\ exams\\:\\ 0\\.005843261958114073\ \(0\)\
\-\ likely\\:\\ 0\\.005836053186284882\ \(0\)\
\-\ this\\:\\ 0\\.00581802187236158\ \(0\)\
\-\ t2w\\:\\ 0\\.005799233333209865\ \(0\)\
\-\ sphenoid\\:\\ 0\\.005756749895181695\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.005756749895181695\ \(0\)\
\-\ females\\:\\ 0\\.005756749895181695\ \(0\)\
\-\ neurofibroma\\:\\ 0\\.005736054455279393\ \(0\)\
\-\ rapidly\\:\\ 0\\.005736054455279393\ \(0\)\
\-\ makes\\:\\ 0\\.005736054455279393\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.0057157068544121045\ \(0\)\
\-\ juvenile\\:\\ 0\\.005637573051582114\ \(0\)\
\-\ 2\\-3\\:\\ 0\\.0055821135648614194\ \(0\)\
\-\ 2004\\:\\ 0\\.005564177625654227\ \(0\)\
\-\ make\\:\\ 0\\.005529083755347626\ \(0\)\
\-\ \\:\\:\\ 0\\.005473485791722349\ \(0\)\
\-\ signal\\:\\ 0\\.005455385787585421\ \(0\)\
\-\ pilocytic\\:\\ 0\\.005445557276549865\ \(0\)\
\-\ than\\:\\ 0\\.005421425798833594\ \(0\)\
\-\ 29\\:\\ 0\\.005398074572974463\ \(0\)\
\-\ remains\\:\\ 0\\.005382652023607115\ \(0\)\
\-\ radiologic\\:\\ 0\\.005382652023607115\ \(0\)\
\-\ each\\:\\ 0\\.005352384103261573\ \(0\)\
\-\ better\\:\\ 0\\.005337529269615309\ \(0\)\
\-\ atrophy\\:\\ 0\\.005337529269615309\ \(0\)\
\-\ always\\:\\ 0\\.005322854498995036\ \(0\)\
\-\ wnl\\:\\ 0\\.005308355478357366\ \(0\)\
\-\ possibly\\:\\ 0\\.0052940280477919875\ \(0\)\
\-\ painless\\:\\ 0\\.005198220153653097\ \(0\)\
\-\ more\\:\\ 0\\.005174761039496771\ \(0\)\
\-\ thus\\:\\ 0\\.005146695196729616\ \(0\)\
\-\ series\\:\\ 0\\.005146695196729616\ \(0\)\
\-\ physical\\:\\ 0\\.005076283945717284\ \(0\)\
\-\ higher\\:\\ 0\\.005073299770801728\ \(0\)\
\-\ interval\\:\\ 0\\.005073299770801728\ \(0\)\
\-\ part\\:\\ 0\\.005015362699158102\ \(0\)\
\-\ pediatric\\:\\ 0\\.004981886268975886\ \(0\)\
\-\ invasion\\:\\ 0\\.004981886268975886\ \(0\)\
\-\ suspicious\\:\\ 0\\.004981886268975886\ \(0\)\
\-\ again\\:\\ 0\\.004970930051639425\ \(0\)\
\-\ avm\\:\\ 0\\.004928070575790857\ \(0\)\
\-\ \\;\\:\\ 0\\.004904167526519597\ \(0\)\
\-\ 80\\:\\ 0\\.004866498642094137\ \(0\)\
\-\ teratoma\\:\\ 0\\.004836848496805643\ \(0\)\
\-\ form\\:\\ 0\\.004836848496805643\ \(0\)\
\-\ cavernous\\:\\ 0\\.004798411816037387\ \(0\)\
\-\ much\\:\\ 0\\.004788990338504632\ \(0\)\
\-\ regular\\:\\ 0\\.004770364528771606\ \(0\)\
\-\ other\\:\\ 0\\.004769100602185106\ \(0\)\
\-\ decrease\\:\\ 0\\.004733951144707105\ \(0\)\
\-\ schwannoma\\:\\ 0\\.0047250163901095\ \(0\)\
\-\ as\\:\\ 0\\.004694591425765598\ \(0\)\
\-\ visual\\:\\ 0\\.004689922519802899\ \(0\)\
\-\ generally\\:\\ 0\\.004655817341877116\ \(0\)\
\-\ intervention\\:\\ 0\\.004606396041005136\ \(0\)\
\-\ either\\:\\ 0\\.004505772667263603\ \(0\)\
\-\ had\\:\\ 0\\.0044645274073624895\ \(0\)\
\-\ gland\\:\\ 0\\.004406015364882166\ \(0\)\
\-\ and\\/or\\:\\ 0\\.004372290238365258\ \(0\)\
\-\ 40\\:\\ 0\\.004352497093084956\ \(0\)\
\-\ caused\\:\\ 0\\.0043394791853655105\ \(0\)\
\-\ eye\\:\\ 0\\.0043394791853655105\ \(0\)\
\-\ a\\:\\ 0\\.004321305346691781\ \(0\)\
\-\ around\\:\\ 0\\.004307533961184887\ \(0\)\
\-\ an\\:\\ 0\\.0042917610082980505\ \(0\)\
\-\ done\\:\\ 0\\.004288763759567496\ \(0\)\
\-\ recommended\\:\\ 0\\.004288763759567496\ \(0\)\
\-\ stable\\:\\ 0\\.0042641811128837845\ \(0\)\
\-\ appear\\:\\ 0\\.004234138535257\ \(0\)\
\-\ treatment\\:\\ 0\\.004187934526878661\ \(0\)\
\-\ visualized\\:\\ 0\\.004187569188007852\ \(0\)\
\-\ bony\\:\\ 0\\.004137234530809619\ \(0\)\
\-\ conservative\\:\\ 0\\.004131768816094696\ \(0\)\
\-\ solid\\:\\ 0\\.004126327666472615\ \(0\)\
\-\ 15\\:\\ 0\\.004126327666472615\ \(0\)\
\-\ of\\:\\ 0\\.00409032714666061\ \(0\)\
\-\ progressive\\:\\ 0\\.00408890934024613\ \(0\)\
\-\ in\\:\\ 0\\.0040813291054746246\ \(0\)\
\-\ minimal\\:\\ 0\\.004073220303148666\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.004017373121880504\ \(0\)\
\-\ process\\:\\ 0\\.0039831301269185404\ \(0\)\
\-\ structures\\:\\ 0\\.0039831301269185404\ \(0\)\
\-\ result\\:\\ 0\\.003968745952721503\ \(0\)\
\-\ used\\:\\ 0\\.003968745952721503\ \(0\)\
\-\ management\\:\\ 0\\.003903791093771963\ \(0\)\
\-\ 8\\:\\ 0\\.0038681810632558698\ \(0\)\
\-\ studies\\:\\ 0\\.003863802563897288\ \(0\)\
\-\ appears\\:\\ 0\\.0038507612842581702\ \(0\)\
\-\ since\\:\\ 0\\.00379995716912617\ \(0\)\
\-\ intact\\:\\ 0\\.00379995716912617\ \(0\)\
\-\ congenital\\:\\ 0\\.003783485435402467\ \(0\)\
\-\ 20\\:\\ 0\\.003719752101885007\ \(0\)\
\-\ otherwise\\:\\ 0\\.003715878006569425\ \(0\)\
\-\ then\\:\\ 0\\.0036815579641913923\ \(0\)\
\-\ signs\\:\\ 0\\.003640890961242197\ \(0\)\
\-\ complete\\:\\ 0\\.003640890961242197\ \(0\)\
\-\ involving\\:\\ 0\\.00363003300726791\ \(0\)\
\-\ because\\:\\ 0\\.0036192715697167654\ \(0\)\
\-\ being\\:\\ 0\\.0036050701898311848\ \(0\)\
\-\ inflammatory\\:\\ 0\\.0035875495692397385\ \(0\)\
\-\ that\\:\\ 0\\.0035738032168494516\ \(0\)\
\-\ less\\:\\ 0\\.0035035593272671702\ \(0\)\
\-\ although\\:\\ 0\\.0034938611144995206\ \(0\)\
\-\ 10\\:\\ 0\\.00348743853310764\ \(0\)\
\-\ type\\:\\ 0\\.00348743853310764\ \(0\)\
\-\ available\\:\\ 0\\.003477868097869004\ \(0\)\
\-\ radiation\\:\\ 0\\.003394977299712272\ \(0\)\
\-\ several\\:\\ 0\\.0033257782514798883\ \(0\)\
\-\ between\\:\\ 0\\.0032790502859857676\ \(0\)\
\-\ right\\:\\ 0\\.003274691437447034\ \(0\)\
\-\ age\\:\\ 0\\.00314880184690594\ \(0\)\
\-\ some\\:\\ 0\\.003141559629378643\ \(0\)\
\-\ patient\\:\\ 0\\.00311110870792877\ \(0\)\
\-\ treated\\:\\ 0\\.003096671714387239\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.00309204205768215\ \(0\)\
\-\ 6\\:\\ 0\\.0030897338515434316\ \(0\)\
\-\ there\\:\\ 0\\.0030792144224333867\ \(0\)\
\-\ decreased\\:\\ 0\\.003075976274484939\ \(0\)\
\-\ years\\:\\ 0\\.0030378246210877513\ \(0\)\
\-\ infection\\:\\ 0\\.0030072839879816066\ \(0\)\
\-\ y\\.o\\:\\ 0\\.00298593151644879\ \(0\)\
\-\ cystic\\:\\ 0\\.002983816836866536\ \(0\)\
\-\ changes\\:\\ 0\\.00296494912377126\ \(0\)\
\-\ edema\\:\\ 0\\.0029260574932582213\ \(0\)\
\-\ time\\:\\ 0\\.0029220353840669643\ \(0\)\
\-\ ct\\:\\ 0\\.0028941977079710484\ \(0\)\
\-\ shows\\:\\ 0\\.0028442780868388365\ \(0\)\
\-\ months\\:\\ 0\\.002825594787760372\ \(0\)\
\-\ been\\:\\ 0\\.0028145216579467205\ \(0\)\
\-\ if\\:\\ 0\\.0028071954404123916\ \(0\)\
\-\ cell\\:\\ 0\\.0027944802803649958\ \(0\)\
\-\ up\\:\\ 0\\.002781897277305355\ \(0\)\
\-\ enhancement\\:\\ 0\\.0027729888209721987\ \(0\)\
\-\ due\\:\\ 0\\.002760626093163244\ \(0\)\
\-\ mild\\:\\ 0\\.002724277789262878\ \(0\)\
\-\ these\\:\\ 0\\.002692305922467119\ \(0\)\
\-\ both\\:\\ 0\\.0026418886085788395\ \(0\)\
\-\ symptoms\\:\\ 0\\.0025782778170679653\ \(0\)\
\-\ surgery\\:\\ 0\\.002512105404794522\ \(0\)\
\-\ bilateral\\:\\ 0\\.0025106752170877046\ \(0\)\
\-\ 1\\:\\ 0\\.0024616541984984345\ \(0\)\
\-\ noted\\:\\ 0\\.0024520837632597985\ \(0\)\
\-\ associated\\:\\ 0\\.0024412379684112615\ \(0\)\
\-\ imaging\\:\\ 0\\.002423818189413563\ \(0\)\
\-\ can\\:\\ 0\\.0023465161652167915\ \(0\)\
\-\ contrast\\:\\ 0\\.002315709063932089\ \(0\)\
\-\ exam\\:\\ 0\\.002272680314708884\ \(0\)\
\-\ 2\\:\\ 0\\.002227729414661678\ \(0\)\
\-\ but\\:\\ 0\\.0022064204612996826\ \(0\)\
\-\ findings\\:\\ 0\\.0022019817624575784\ \(0\)\
\-\ surgical\\:\\ 0\\.0021746026274230674\ \(0\)\
\-\ presents\\:\\ 0\\.002113370817806206\ \(0\)\
\-\ also\\:\\ 0\\.0020394910334989727\ \(0\)\
\-\ within\\:\\ 0\\.001973524707489203\ \(0\)\
\-\ on\\:\\ 0\\.0017527627418049106\ \(0\)\
\-\ with\\:\\ 0\\.0016998185388361706\ \(0\)\
\-\ disease\\:\\ 0\\.0016909655462659858\ \(0\)\
\-\ not\\:\\ 0\\.001494937859251738\ \(0\)\
\-\ at\\:\\ 0\\.0014016503060915655\ \(0\)\
\-\ \\.\\:\\ 0\\.0011603964583878322\ \(0\)\
\-\ year\\:\\ 0\\.001157512432533795\ \(0\)\
